Anbio Biotechnology is a medical technology company focused on the development and supply of in vitro diagnostic products. The company designs assays that detect biomarkers related to infectious diseases cancer cardiovascular conditions inflammation drug abuse endocrine disorders renal disease pharmacogenomics and diabetes. It works with third party laboratories to create the assays and then contracts manufacturers to produce the final products for sale.
Revenue comes from…
Anbio Biotechnology is a medical technology company focused on the development and supply of in vitro diagnostic products. The company designs assays that detect biomarkers related to infectious diseases cancer cardiovascular conditions inflammation drug abuse endocrine disorders renal disease pharmacogenomics and diabetes. It works with third party laboratories to create the assays and then contracts manufacturers to produce the final products for sale.
Revenue comes from the sale of its in vitro diagnostic kits and instruments across multiple technology platforms. In 2025 the company reported total revenue of $8.65 million with approximately 20 percent derived from respiratory disease and COVID 19 related antigen tests. Additional revenue is generated from lateral flow immunoassays fluorescence immunoassays loop mediated isothermal amplification dry chemistry chemiluminescence immunoassay and real time PCR products. The company sells through a network of distributors and direct sales teams serving hospitals clinics laboratories and other healthcare providers in Europe Asia Pacific the Americas and Africa.
Anbio Biotechnology positions itself as a provider of low cost rapid diagnostic solutions that emphasize speed innovation and accessibility. The company differentiates itself from other diagnostic solution firms by focusing on easy to use point of care tests that deliver results within minutes without requiring expensive instrumentation. Its competitive advantages include a broad product portfolio covering many disease areas a partnership model that retains intellectual property rights and a management team with extensive experience in the diagnostics sector.
The company serves a diverse customer base that includes hospitals private clinics laboratories public health agencies and distributors. In 2025 two customers accounted for roughly 12 percent and 35 percent of total revenue while no specific customer names are disclosed. Its distribution network spans countries in the European Union Asia Pacific Africa and the Americas supporting commercialization of its CE marked IVD products.